Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers

被引：85

作者：

Vaughn, DW

Hoke, CH

Yoksan, S

LaChance, R

Innis, BL

Rice, RM

Bhamarapravati, N

机构：

[1] WALTER REED ARMY INST RES, WASHINGTON, DC 20307 USA

[2] MAHIDOL UNIV, CTR VACCINE DEV, SALAYA, THAILAND

[3] USA, MED RES INST INFECT DIS, FREDERICK, MD 21702 USA

[4] USA, MED MAT DEV ACT, FREDERICK, MD 21702 USA

来源：

VACCINE | 1996年 / 14卷 / 04期

关键词：

live-attenuated vaccines; dengue; clinical trial;

D O I：

10.1016/0264-410X(95)00167-Y

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A live-attenuated dengue 2 vaccine (strain 16681 PDK 53) developed at Mahidol University, Thailand was evaluated for safety and immunogenicity by administering 10(4) p.f.u. subcutaneously to ten flavivirus non-immune American volunteers. The vaccine was safe, there were no serious adverse reactions. Eight recipients experienced no or mild side effects. One recipient reported headaches on 7 separate clays. One volunteer, who had a fracture of the humerus 1 day after vaccination requiring surgical repair, experienced generalized malaise with fever (maximum temperature=38.9 degrees C), headache, eye pain and myalgia lasting less than 24 h. The vaccine was highly immunogenic, all recipients developed neutralizing antibody that persisted for two years. Copyright (C) 1996 Published by Elsevier Science Ltd.

引用

页码：329 / 336

页数：8

共 14 条

[1]

BELLANTI JA, 1966, B WORLD HEALTH ORGAN, V35, P93

[2]

BHAMARAPRAVATI N, 1989, LANCET, V1, P1077

[3]

BHAMARAPRAVATI N, 1987, B WORLD HEALTH ORGAN, V65, P189

[4] FROM THE WORLD-HEALTH-ORGANIZATION - DEVELOPMENT OF DENGUE AND JAPANESE ENCEPHALITIS VACCINES [J].